• Small intestinal bacterial overgrowth (SIBO) is characterized by excessive proliferation of colonic bacterial species in the small bowel.
• Symptoms related to this disorder are abdominal discomfort, diarrhoea, malnutrition, vitamin D deficiency, intestinal and systemic inflammation, susceptibility to bloodstream infection, and growth failure, which are also common features of protein-losing enteropathy (PLE) in Fontan patients.
• We postulated that Fontan patients with PLE may be at risk for developing small intestinal bacterial overgrowth.
• The aim of this study was to test failing Fontan patients for the presence of SIBO with an intention-to-treat.
• Six Fontan patients (n = 5 with chronic relapsing PLE, n = 1 with newly diagnosed PLE) were scheduled for a glucose hydrogen breath test (GHBT) between June 2013 and December 2015 at our institution.
• Medical charts were reviewed for cardiac diagnosis, demographics, gastrointestinal signs and symptoms, serum albumin, 25-OH-Vtamin D, Vitamin B12, fecal calprotectin and alpha-1 antitrypsin levels.
• Vitamin B12 and vitamin D deficiencies were defined as a serum level < 300 pg/mL and a serum 25-OH-D level of <20 ng/mL
• SIBO was diagnosed if a fasting breath hydrogen concentration was ≥ 10 ppm or an increase in hydrogen levels of ≥ 12 ppm above the baseline value was measured after ingestion of glucose.
• One patient was not able to drink the glucose solution and was excluded from the study.
• Six Fontan patients (median age 7.5 yrs, 83.3% male) underwent a glucose hydrogen breath test (chronic PLE: n = 4; newly diagnosed PLE: n = 1; failing Fontan: n = 1).
• Patient demographics and clinical characteristics are presented in TABLE 1.
• All Fontan patients experienced gastrointestinal complaints (pain, swelling, no appetite, discomfort).
• Results of the GHBT test are shown in TABLE 2.
• Patients with SIBO were treated with Rifaximin (200 mg once daily for 12 days), followed by a mixture of several probiotic preparations (Ominflora, Colibiogen, Pro-Symbioflor) as maintenance therapy.
• We identified an additional pathophysiological mechanism that might contribute to long-term outcome in these patients.
• SIBO seems a common finding in Fontan patients with overt PLE (33.3%).
• Alterations in the gut microbiome may complicate the course of disease in Fontan patients with PLE.
• Patients can be successfully treated with rifaximin and oral probiotics.
• Vitamin B12 deficiency accompanied all cases of SIBO.
• Screening Fontan patients with PLE for SIBO seems mandatory. 
